Broadening the Therapeutic Armamentarium Against Plaque Psoriasis

Psoriasis Resources and Associations

Resource	Address
Armstrong A, et al. Impact of psoriatic disease on quality of life: Interim results of a global survey. *Dermatol Ther (Heidelb)*. 2022;12(4):1055-1064. doi:10.1007/s13555-022-00695-0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918421/
Bugaut H, et al. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. *Front Immunol*. 2021;12:621956. doi:10.3389/fimmu.2021.621956	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948519/
Bakshi H, et al. Treatment of psoriasis: A comprehensive review of entire therapies. *Curr Drug Saf*. 2020;15(2):82-104. doi:10.2174/1574886315666200128095958	https://pubmed.ncbi.nlm.nih.gov/31994468/
Boehncke W, et al. Unmet needs in the field of psoriasis: Pathogenesis and treatment. *Clin Rev Allergy Immunol.* 2018;55(3):295-311. doi:10.1007/s12016-017-8634-3	https://pubmed.ncbi.nlm.nih.gov/28780731/
Branisteanu DE, et al. Update on the etiopathogenesis of psoriasis (Review). *Exp Ther Med*. 2022;23(3):201. doi:10.3892/etm.2022.11124	https://pubmed.ncbi.nlm.nih.gov/35126704/
Bu J, et al. Epidemiology of psoriasis and comorbid diseases: A narrative review. *Front Immunol*. 2022;13:880201. doi:10.3389/fimmu.2022.880201	https://pubmed.ncbi.nlm.nih.gov/35757712/
Ceccarelli M, et al. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. *Dermatol Ther.* 2021;34(1):e14660. doi:10.1111/dth.14660	https://pubmed.ncbi.nlm.nih.gov/33301216/
Elwyn G, et al. Shared decision making: A model for clinical practice. *J Gen Intern Med*. 2012;27(10):1361-1367. doi:10.1007/s11606-012-2077-6	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445676/
Gelfand J, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. *J Am Acad Dermatol*. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058	https://pubmed.ncbi.nlm.nih.gov/33422626/
Ghoreschi K, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. *Lancet*. 2021;397(10275):754-766. doi:10.1016/S0140-6736(21)00184-7	https://pubmed.ncbi.nlm.nih.gov/33515492/

Resource	Address
Hawkes J, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. *J Immunol*. 2018;201(6):1605-1613. doi:10.4049/jimmunol.1800013	https://pubmed.ncbi.nlm.nih.gov/30181299/
Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities? *J Invest Dermatol*. 2017;137(8):1612-1613. doi:10.1016/j.jid.2017.06.001	https://pubmed.ncbi.nlm.nih.gov/28735613/
Boutet M, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of Its divergence in skin and joints. *Int J Mol Sci*. 2018;19(2):530. doi:10.3390/ijms19020530	https://pubmed.ncbi.nlm.nih.gov/29425183/
Ogawa E, et al. Pathogenesis of psoriasis and development of treatment. *J Dermatol*. 2018;45(3):264-272. doi:10.1111/1346-8138.14139	https://pubmed.ncbi.nlm.nih.gov/29226422/
Raharja A, et al. Psoriasis: A brief overview. *Clin Med (Lond)*. 2021;21(3):170-173. doi:10.7861/clinmed.2021-0257	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140694/
Radi G, et al. Novel therapeutic approaches and targets for treatment of psoriasis. *Curr Pharm Biotechnol*. 2021;22(1):7-31. doi:10.2174/1389201021666200629150231	https://pubmed.ncbi.nlm.nih.gov/32598253/
Sangha AM. Special considerations in the diagnosis and treatment of psoriasis. *J Clin Aesthet Dermatol*. 2021;14(12 suppl 1):S24-S25.	https://pubmed.ncbi.nlm.nih.gov/35291258/
Sbidian E, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. *Cochrane Database Syst Rev*. 2020;1(1):CD011535. doi:10.1002/14651858.CD011535.pub3	https://pubmed.ncbi.nlm.nih.gov/31917873/
Schlapbach C, et al. TYK-ing all the boxes in psoriasis. *J Allergy Clin Immunol*. 2022;149(6):1936-1939. doi:10.1016/j.jaci.2022.03.014	https://www.jacionline.org/article/S0091-6749(22)00386-4/fulltext
Takeshita J, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. *J Am Acad Dermatol.* 2014;71(4):633-641. doi:10.1016/j.jaad.2014.05.001	https://pubmed.ncbi.nlm.nih.gov/24928705/
Takeshita J, et al. Psoriasis and comorbid diseases: Implications for management. *J Am Acad Dermatol*. 2017;76(3):393-403. doi:10.1016/j.jaad.2016.07.065	https://pubmed.ncbi.nlm.nih.gov/28212760/
Tokuyama M, et al. New treatment addressing the pathogenesis of psoriasis. *Int J Mol Sci*. 2020;21(20):7488. doi:10.3390/ijms21207488	https://pubmed.ncbi.nlm.nih.gov/33050592/
Truong T, et al. Deucravacitinib: The first FDA-approved oral TYK2 inhibitor for moderate to severe plaque psoriasis. *Ann Pharmacother*. 2023 Jun 21. doi: 10.1177/10600280231153863.	https://pubmed.ncbi.nlm.nih.gov/37341177/

Resource	Address
Vu A, et al. Deucravacitinib in moderate-to-severe psoriasis. *Immunotherapy*. 2022;14:1279-90. DOI: 10.2217/imt-2022-0109.	https://pubmed.ncbi.nlm.nih.gov/36373503/
Yang K, et al. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review. *Am J Clin Dermatol*. 2021;22(2):173-192. doi:10.1007/s40257-020-00578-0	https://pubmed.ncbi.nlm.nih.gov/33301128/

Psoriasis Associations and Foundations

Resource	Address
American Academy of Dermatology Association	https://www.aad.org/public/diseases/psoriasis
American Dermatological Association	https://ada1.org/
National Institute of Arthritis and Musculoskeletal and Skin Diseases	https://www.niams.nih.gov/health-topics/psoriasis/diagnosis-treatment-and-steps-to-take
National Psoriasis Foundation	https://www.psoriasis.org/
Psoriasis and Psoriatic Arthritis Alliance	https://www.papaa.org/